Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/279,194external-prioritypatent/US5138069A/en
Priority claimed from SU894613475Aexternal-prioritypatent/RU1814646C/en
Application filed by E.I. Du Pont De Nemours And CompanyfiledCriticalE.I. Du Pont De Nemours And Company
Publication of MD28B1publicationCriticalpatent/MD28B1/en
Publication of MD28C2publicationCriticalpatent/MD28C2/en
The use: In it's capacity of inhibitory of the agiottensine hormone. The essence: the product with a general formula:where R1 represents COOH or the groupR2 represents n-propyl or n-butyl,R3CZ, CF3, C2F5, C6H5 or COOH;R4 represents COOH; or CHO or CH2OH with the condition that then R4 represents CH2OH, R3 represents C2F5 and R2 represents n-propyl;(b) when R3 represents COOH, R4 is also COOH;(c) when R2 represents n-propyl, R3 represents C2F5 and R4 represents COOH, R1 constitutes the groupReagent 1: Product with formulawhere R2 has the indicated values: R5 represents CZ, CF3, C2F3, C6H5 or COO (C1-4 - alkyl; R6 represents CH2OH, CO2 (C1-4-alkyl) or CHO)).Reagent 2: Product with formulawhere X represents halogen, n represents toluene sylphonic or methylsulphonilox; R7 represents COO (C1-4 - alkyl), CN or the groupThe temperature of the dissolvent. A base is the catalyst.
MD94-0091A1988-01-071994-03-16The method of obtaining the imidazole's derivatives
MD28C2
(en)